ArticleBlood cancer journal2026

Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine.

Ting Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.